IFET has ensured full and uninterrupted access to trimethoprim/sulfamethoxazole antibiotics for patients

In response to recent inaccurate public statements regarding a shortage of the antibiotic combination trimethoprim/sulfamethoxazole, IFET S.A. clarifies the following:

• Available stock is sufficient for a period exceeding three months.
• Following instructions from the :contentReference[oaicite:1]{index=1}, the company continues without interruption the import and distribution of both the injectable and oral forms of the respective product.
• Hospitals and pharmaceutical warehouses are supplied with the required quantities through a normal supply flow.
• Since 2013, IFET S.A. has consistently ensured coverage of therapeutic needs by providing the corresponding product in oral suspension form.

IFET S.A., in close cooperation with the EOF, continuously monitors the needs of the healthcare system and intervenes where necessary, prioritizing uninterrupted patient access to essential treatments.